Barclays Maintains an 'Overweight' on CVS Caremark (CVS); Review of Recent Management Meetings
Tweet Send to a Friend
Barclays maintains an 'Overweight' on CVS Caremark (NYSE: CVS), PT $37.
Barclays analyst says, "After two days of meetings with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "After two days of meetings with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
